We can't find the internet
Attempting to reconnect
14446.1 PFLS-LS
Bi-specific antibody-based molecules for simultaneous targeting of carbonic anhydrases IX and XII as a unique and novel cancer treatment
Zusammenfassung
Bi-specific antibody-based molecules for simultaneous targeting of carbonic anhydrases IX and XII as a unique and novel cancer treatment
Weitere Texte
Abstract
Tumor cells escape poor oxygenation (hypoxia) by overexpression of Carbonic Anhydrases (CA), in particular CAIX and CAXII, which leads to a growth advantage with|increased metastasis formation and poor patient survival. siRNA targeting of both CA proteins reduces tumor growth in animal models but is hardly applicable in the clinic due to unfavourable in vivo PK/PD properties. As a novel therapeutic approach, we will generate fully human CAIX and CAXII inhibiting antibodies and combine them in a new bi-specific antibody format to target both CAs simultaneously.
Beteiligte
Marc van Dijk
Wirtschaftspartner
4-Antibody AG Pharmazentrum Marc van Dijk Hochbergerstrasse 60c 4057 Basel BS CH
Christoph Renner
Kontaktperson
christoph.renner@unibas.ch
Universitätsspital Basel Christoph Renner Spitalstrasse 21 / Petersgraben 4 4031 Basel BS CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2013-06-30
- Enddatum
- 2015-12-31
- Bewilligte Gesamtkosten
- CHF 371058.00
- Sektion
- 20 Förderbereich Life Sciences
- NABS Politikbereich
- Industrielle Produktivität und Technologie
Forschungsdisziplinen
- T490 Biotechnology 100.0%